Revisiting the sealed heating method–V158411 decreases Chk1 nuclear immunofluorescence in HT29 cells heated in a low well volume. by Andrew J. Massey (239469)

Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

“…<p>(A) Turnover rates, as measured by 5-HIAA:5-HT ratios, normalized to the values of vehicle-treated animals, for the following drugs: fluoxetine (FLX; chronic treatment with 10 mg/kg); chlordiazepoxide (CDZ; 0.02 mg/kg); clonazepam (CLZ; 0.05 mg/kg); diazepam (DZP; 1.25 mg/kg); buspirone (BUS; 50 mg/kg); ethanol (EtOH, 2.5%); dizocilpine (MK; 0.005 mg/kg); verapamil (VER; 5 mg/kg); WAY 100,635 (WAY; 0.03 mg/kg); and SB 224,289 (SB; 2.5 mg/kg). …”

Revisiting the sealed heating method–heating cells in a low volume decreases nuclear Chk1. by Andrew J. Massey (239469)

Structurally distinct inhibitors of Chk1 decrease Chk1 nuclear fluorescence following heating in a low well volume. by Andrew J. Massey (239469)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Activation of MAPKs in HCS-2/8 cells treated with 5-HT or agonist of each 5-HT₂ receptor and rescue effect of inhibitors of ERK1/2 and JNK on the BW723C86-decreased CCN2 production. by Ayaka Hori (4597795)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Surface tension versus time of the MHS solution (50 mM) and LNC dispersion containing 50 mM MHS as determined by drop tensiometry. by Celia R. A. Mouzouvi (4347937)

Definitions of the features selected [50]. by Yu Zhang (12946)

CK1δ-specific kinase activity in HT1080 cells is decreased after activation of Chk1. by Joachim Bischof (189845)

Topography of the relationship between the change in alpha power decrease and the change in M50 gating ratio. by Tzvetan Popov (315385)

“…B: Relationship between change in alpha power decrease (abscissa, negative values indicate improvement) and pre-to-post-training change in M50 gating ratio (ordinate, positive values indicate changes towards normal, that is, smaller gating ratio) by patient training group based on the ROI in 4A.…”

Cell adhesion to fibronectin is decreased with 50 µM 4N1K treatment. by Pascal Leclair (566971)